You are here: Home » Reuters » News
Business Standard

Pfizer rolls back drug price hikes temporarily after talking with Trump

The Trump administration has not yet taken significant action to lower drug prices

Reuters  |  Washington/New York 

Photo courtesy: Reuters
Photo courtesy: Reuters

Inc said on Tuesday it was deferring drug price increases for no more than six months after the company's had an extensive conversation with US

The rollback came a day after Trump took aim at and other US drugmakers for raising prices on some of their medicines, saying in a tweet that they "should be ashamed" and that his administration would respond.

on Tuesday said it would defer price increases that went into effect on July 1 until the end of the year or until the president's drug pricing blueprint goes into effect - whichever is sooner. The company said it would return drug prices to their pre-July 1 levels as soon as technically possible.

On Tuesday, Trump said in a tweet that Pfizer had agreed to roll back drug price hikes after he and US Health and spoke with the company's CEO,

"We applaud Pfizer for this decision and hope other companies do the same," Trump, who is travelling in Europe, said in a tweet.

Pfizer, one of the largest companies, now likely will not raise drug prices until after the 2018 midterm elections in November. That gives Trump, who made lowering prescription drug prices a top 2016 presidential campaign issue, a short-term victory he can point to in the run-up to the elections, which are being closely watched to see if Trump's fellow Republicans will be able to maintain control of both the and the

Pfizer raised list prices on around 40 medicines earlier this month. Those include Viagra, cholesterol drug and treatment Xeljanz, according to List prices do not include rebates and discounts drugmakers may offer.

The has not yet taken significant action to lower drug prices. Azar has said lowering prices long term will take years because of the complexity of the

Trump rolled out a blueprint in May on how his administration planned to lower drug prices. Trump said in May that some drug companies would announce "voluntary, massive" price decreases in two weeks, though none have materialized yet.

company shares rose after Trump unveiled his drug pricing blueprint.

Azar praised Pfizer on Tuesday. "I commend Pfizer for its constructive and professional approach, and its desire to work with Trump to be part of the solution and not part of the problem," he said in a statement.


First Published: Wed, July 11 2018. 12:25 IST